JP7358236B2 - 腫瘍溶解性ウイルスを腫瘍に標的化する方法 - Google Patents

腫瘍溶解性ウイルスを腫瘍に標的化する方法 Download PDF

Info

Publication number
JP7358236B2
JP7358236B2 JP2019515539A JP2019515539A JP7358236B2 JP 7358236 B2 JP7358236 B2 JP 7358236B2 JP 2019515539 A JP2019515539 A JP 2019515539A JP 2019515539 A JP2019515539 A JP 2019515539A JP 7358236 B2 JP7358236 B2 JP 7358236B2
Authority
JP
Japan
Prior art keywords
ido
mscs
cancer
cells
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532635A (ja
JP2019532635A5 (enExample
Inventor
エス． モハパトラ、シャム
モハパトラ、スブーラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Veterans Affairs
Original Assignee
United States Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Veterans Affairs filed Critical United States Department of Veterans Affairs
Publication of JP2019532635A publication Critical patent/JP2019532635A/ja
Publication of JP2019532635A5 publication Critical patent/JP2019532635A5/ja
Application granted granted Critical
Publication of JP7358236B2 publication Critical patent/JP7358236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18532—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019515539A 2016-09-19 2017-09-19 腫瘍溶解性ウイルスを腫瘍に標的化する方法 Active JP7358236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396604P 2016-09-19 2016-09-19
US62/396,604 2016-09-19
PCT/US2017/052313 WO2018053529A1 (en) 2016-09-19 2017-09-19 Method of targeting oncolytic viruses to tumors

Publications (3)

Publication Number Publication Date
JP2019532635A JP2019532635A (ja) 2019-11-14
JP2019532635A5 JP2019532635A5 (enExample) 2020-10-15
JP7358236B2 true JP7358236B2 (ja) 2023-10-10

Family

ID=61619005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515539A Active JP7358236B2 (ja) 2016-09-19 2017-09-19 腫瘍溶解性ウイルスを腫瘍に標的化する方法

Country Status (5)

Country Link
US (2) US11607426B2 (enExample)
EP (2) EP4268838B1 (enExample)
JP (1) JP7358236B2 (enExample)
CA (1) CA3037333A1 (enExample)
WO (1) WO2018053529A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
KR20220038485A (ko) * 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
KR102233568B1 (ko) * 2019-12-13 2021-03-30 주식회사 알바이오 항암 바이러스가 도입된 중간엽 줄기세포의 세포 생존능을 향상시키는 방법
CN115996735A (zh) * 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529082A (ja) 2010-05-18 2013-07-18 ウエイドン、チャン 遺伝子組み換えｒｓウイルスを使用した乳がん治療
JP2016504324A (ja) 2012-12-14 2016-02-12 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 幹細胞の免疫制御作用を調節する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
WO2014160475A1 (en) * 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2902174A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529082A (ja) 2010-05-18 2013-07-18 ウエイドン、チャン 遺伝子組み換えｒｓウイルスを使用した乳がん治療
JP2016504324A (ja) 2012-12-14 2016-02-12 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 幹細胞の免疫制御作用を調節する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
難波宏樹，幹細胞を用いた悪性グリオーマの遺伝子治療，Neuro-Oncologyの進歩，2016年04月28日，Vol. 23, No. 1，p. 21-26

Also Published As

Publication number Publication date
EP4268838A2 (en) 2023-11-01
EP3515462B1 (en) 2023-06-14
US20230364147A1 (en) 2023-11-16
EP3515462A4 (en) 2020-04-15
EP3515462A1 (en) 2019-07-31
EP4268838B1 (en) 2026-07-29
US11607426B2 (en) 2023-03-21
EP4268838A3 (en) 2023-12-27
JP2019532635A (ja) 2019-11-14
WO2018053529A1 (en) 2018-03-22
US20190216855A1 (en) 2019-07-18
CA3037333A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
Di et al. Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells
EP3400293B2 (en) Modified oncolytic virus
US20190022203A1 (en) Oncolytic virus and checkpoint inhibitor combination therapy
JP2014527983A (ja) 癌免疫療法
JP7239910B2 (ja) 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用
JP2018519262A (ja) 樹状細胞免疫療法
Chaurasiya et al. Viroimmunotherapy for breast cancer: Promises, problems and future directions
KR20150087270A (ko) Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
US20230364147A1 (en) Method of targeting oncolytic viruses to tumors
US20250332235A1 (en) Breast cancer tumor cell vaccines
CN112004545B (zh) 免疫-溶瘤的经修饰的痘苗天坛病毒和治疗癌症的方法
US11524047B2 (en) Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient
CN111849905B (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
Bian et al. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein
Shi et al. Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis
US20090093429A1 (en) Combination therapy for treating cancer
KR101651171B1 (ko) Il-12를 발현하는 간엽 줄기세포를 포함하는 간암 치료용 조성물 및 이를 이용한 치료방법
TW201725050A (zh) 抗癌疫苗組合
RU2741228C2 (ru) Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
JP2024529429A (ja) 人工多能性幹細胞に基づくがんワクチン
WO2022011651A1 (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
KR20250057905A (ko) 강화된 적합도 및 우수한 항암 활성을 갖는 변형된 종양용해 파보바이러스 h-1pv
Mauleón Tim-3 blockade as a therapeutic approach for diffuse intrinsic pontine Glioma
Rajwani The role of cancer and non-cancer cell infections in systemic VSV∆ M51 therapy
WO2025234450A1 (ja) 改変がん細胞及びそれを含むがんワクチン組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150